Related Experiment Videos
Community-acquired pneumonia: etiology, diagnosis, and treatment
1Department of Medicine, Kern Medical Center, Bakersfield, California.
Abstract:
Pneumonia is an important cause of morbidity and mortality. A variety of conditions that damage the airways and weaken host defense mechanisms increase the susceptibility of the individual to bacterial colonization of the pulmonary tree. Because the clinician frequently cannot determine the etiologic agent, pneumonia is often treated empirically. Cefonicid, a long-acting cephalosporin, is a useful and cost-effective antibiotic that is active against many of the common pathogens that cause community-acquired pneumonia, such as Streptococcus pneumoniae and Haemophilus influenzae. It is also active against less common community-acquired pathogens, such as Klebsiella pneumoniae, Escherichia coli, and some anaerobic mouth flora. Erythromycin is useful when Mycoplasma or Legionella species are suspected. Cefonicid's demonstrated safety and efficacy, its low cost, and its long half-life, permitting once-daily dosing, make this antibiotic an ideal parenteral choice for empiric therapy of community-acquired pneumonia.
Insights
Cefonicid is a cost-effective antibiotic for treating community-acquired pneumonia empirically. Its long half-life allows once-daily dosing, making it an ideal parenteral choice.
Area of Science:
- Infectious Diseases
- Pharmacology
- Pulmonology
Background:
- Pneumonia is a significant cause of illness and death.
- Compromised airway defenses increase susceptibility to bacterial lung infections.
- Empirical antibiotic therapy is common due to difficulties in identifying specific pathogens.
Purpose of the Study:
- To evaluate cefonicid as an empirical parenteral antibiotic for community-acquired pneumonia.
- To highlight the advantages of cefonicid, including its spectrum of activity, cost-effectiveness, and dosing convenience.
Main Methods:
- This abstract discusses the use of cefonicid for empirical treatment of community-acquired pneumonia.
- It reviews the spectrum of activity of cefonicid against common and less common pneumonia pathogens.
- The pharmacokinetic properties, safety, efficacy, and cost-effectiveness of cefonicid are considered.
Main Results:
- Cefonicid exhibits activity against common pathogens like Streptococcus pneumoniae and Haemophilus influenzae.
- It is also effective against less common pathogens including Klebsiella pneumoniae, Escherichia coli, and anaerobic flora.
- Erythromycin is recommended for suspected Mycoplasma or Legionella infections.
Conclusions:
- Cefonicid is a safe, effective, and cost-efficient parenteral antibiotic for empirical community-acquired pneumonia treatment.
- Its long half-life enables convenient once-daily dosing.
- Cefonicid is an ideal choice for parenteral empirical therapy of community-acquired pneumonia.